Page 4 - புளோரியன் கிராமர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புளோரியன் கிராமர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புளோரியன் கிராமர் Today - Breaking & Trending Today

The Fiji Times » Global quest underway to speed COVID-19 vaccine trials


Reuters Reuters
21 July, 2021, 2:10 pm
Vials labelled Moderna, Johnson & Johnson, Pfizer-BioNTech coronavirus disease (COVID-19) vaccine are seen in this illustration picture taken May 2, 2021. REUTERS/Dado Ruvic
CHICAGO, July 20 (Reuters) – Scientists are working on a benchmark for COVID-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.
Researchers are trying to determine just what level of COVID-19 antibodies a vaccine must produce to provide protection against the illness. Regulators already use such benchmarks – known as correlates of protection – to evaluate flu vaccines without requiring large, lengthy clinical trials. ....

New York , United States , United Kingdom , Stefano Colloca , Marion Gruber , Stanley Plotkin , Peter Gilbert , Reithera Srl , Florian Krammer , Drug Administration , Researchers At Oxford University , Taiwan Medigen Vaccine Biologics Corp , Icahn School Of Medicine At Mount Sinai , Oxford University , Fred Hutchinson Cancer Research Center , Icahn School , Mount Sinai , Fred Hutchinson Cancer Research , World Health Organization Meeting , Medigen Vaccine Biologics Corp , Ray Jordan , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , மரியன் க்ரூபர் , ஸ்டான்லி பிலொட்கின் ,

Global quest underway to speed up COVID-19 vaccine trials


Jul 21, 2021
CHICAGO – Scientists are working on a benchmark for COVID-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.
Researchers are trying to determine just what level of COVID-19 antibodies a vaccine must produce to provide protection against the illness. Regulators already use such benchmarks known as correlates of protection to evaluate flu vaccines without requiring large, lengthy clinical trials.
“You could use it to predict efficacy from a vaccine, which will be more important as we are less able to conduct placebo-controlled trials,” said Stanley Plotkin, inventor of the Rubella vaccine and an expert on correlates of protection. ....

New York , United States , United Kingdom , Stefano Colloca , Marion Gruber , Stanley Plotkin , Peter Gilbert , Reithera Srl , Florian Krammer , Drug Administration , Researchers At Oxford University , Taiwan Medigen Vaccine Biologics Corp , Icahn School Of Medicine At Mount Sinai , Oxford University , Fred Hutchinson Cancer Research Center , Icahn School , Mount Sinai , Fred Hutchinson Cancer Research , World Health Organization Meeting , Medigen Vaccine Biologics , Ray Jordan , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , மரியன் க்ரூபர் , ஸ்டான்லி பிலொட்கின் ,